Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.74 |
| ▸ | CIT | O14578 | 3/20 | 0.73 |
| ▸ | FLT3 | P36888 | 3/20 | 0.73 |
| ▸ | GSK3B | P49841 | 3/20 | 0.73 |
| ▸ | JAK3 | P52333 | 3/20 | 0.73 |
| ▸ | JAK2 | O60674 | 2/20 | 0.73 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.72 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.72 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.72 |
| ▸ | PRKCG | P05129 | 1/20 | 0.72 |
| ▸ | PRKCB | P05771 | 1/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.72 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.72 |
| ▸ | CDK2 | P24941 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.72 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.72 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13887728 | 0.90 | ROCK1 (0.81) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL13887729 | 0.87 | ROCK1 (1.00) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL13887844 | 0.87 | ROCK1 (0.77) | ROCK1CYP3A4 | |
| SCHEMBL13887913 | 0.87 | ROCK1 (0.77) | ROCK1CYP3A4 | |
| SCHEMBL13887884 | 0.87 | ROCK1 (0.77) | ROCK1CYP3A4 | |
| SCHEMBL4476795 | 0.86 | ROCK1 (0.81) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL4474268 | 0.86 | ROCK1 (1.00) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL13895211 | 0.86 | ROCK1 (0.80) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL13887746 | 0.85 | ROCK1 (0.75) | ROCK1CYP3A4CITFLT3GSK3B | |
| SCHEMBL13887763 | 0.85 | ROCK1 (0.75) | ROCK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514448-B2 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1756108-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-05 | — | — | US | disclosed |
| WO-2005103050-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | ROCK2, ROCK1, TNK2 | ROCK1 2/4885CYP3A4 4258/4885CIT 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.